You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股隨A股同業造好金嗓子(06896.HK)續漲9%創52周高里昂建議長線投資者趁低吸納醫藥股
阿思達克 06-17 14:29

里昂上周四建議長線投資者藉回調吸納醫藥股,本港醫藥板塊今天普遍隨A股同業造好,尤其是金嗓子(06896.HK)三連漲最多累漲23%,高見1.72元,創52周新高,現造1.69元,續漲9%,成交增至206萬股。該公司去年多賺66.5%至1.02億元人民幣,末期股息12港仙(已於5月23日除淨)。

藥明康德(02359.HK)升破50天線(64.72元),最高見72元,現造67元,續升5%;其A股升3.4%高見86.68元人民幣。旗下新藥臨床試驗獲批的復星醫藥(02196.HK)曾一舉重越10天及20天線(21.93元及22.68元),最高見23.05元,現造22.45元,回升3.5%;其A股升4.5%高見24.99元人民幣。

藍籌中生(01177.HK)旗下抗真菌藥獲國家藥監局藥品註冊批件,股價三連彈兼重越100天及10天線,最高見7.37元,現造7.28元,續升2.5%;藍籌石藥(01093.HK)回升1.7%曾高見11.8元;三生製藥(01530.HK)反覆回升1.4%高見12.84元。聯邦制藥(03933.HK)升2%高見4.03元。威高股份(01066.HK)回升3.2%報7.32元,股價重越50天線(7.18元)。白雲山(00874.HK)反覆升3%報33.85元,股價重越10天及、20天及100天線(33.84元)。

內地醫藥板塊今天跑贏大市,其中生物醫藥板塊造好,且11隻個股漲停。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account